US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Pacira BioSciences, Inc. - Common Stock
(NQ:
PCRX
)
25.21
+0.20 (+0.80%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pacira BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Pacira BioSciences Reports First Quarter 2026 Financial Results
April 30, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
April 28, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
April 27, 2026
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --
From
Pacira BioSciences
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Thursday?
↗
April 16, 2026
Via
Chartmill
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case
↗
March 05, 2026
Via
Chartmill
Pacira BioSciences Inc (NASDAQ:PCRX) Misses Q4 Earnings and Revenue Estimates, Shares Drop
↗
February 26, 2026
Via
Chartmill
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
April 16, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
April 13, 2026
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting...
Via
MarketMinute
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
April 13, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
March 30, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
March 11, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
March 04, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
March 02, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira (PCRX) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Pacira (PCRX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
February 26, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
February 12, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
February 12, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
January 28, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
January 13, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
January 08, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
January 07, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Bridge City Capital Loads Up Onto Innovation Stock With Over 31,000 Shares
↗
December 22, 2025
Post-trade holding: 47,342 shares valued at approximately $6.12 million.
Via
The Motley Fool
Topics
Regulatory Compliance
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
December 18, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
December 02, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
November 26, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
November 11, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
November 06, 2025
From
Pacira BioSciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
